What does Acrivon Therapeutics, Inc. do?
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics…
What is Acrivon Therapeutics, Inc.'s P/E and P/B ratio?
Acrivon Therapeutics, Inc. has a P/E ratio of -0.9 and a P/B ratio of 0.87.
What is Acrivon Therapeutics, Inc.'s debt-to-equity ratio?
Acrivon Therapeutics, Inc. has a debt-to-equity ratio of 0.02.
How much does Acrivon Therapeutics, Inc. owe compared with what it owns?
Acrivon Therapeutics, Inc. owes $0.13 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Acrivon Therapeutics, Inc.'s Positivity rank?
Acrivon Therapeutics, Inc. is ranked #2,290 of 6,774 companies globally and #684 of 4,000 in United States on PositoAI, with a Positivity Score of 21,683.
Does Acrivon Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Acrivon Therapeutics, Inc..
Where can I read the latest news about Acrivon Therapeutics, Inc.?
Recent headlines about Acrivon Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Acrivon Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Acrivon Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.